Stay informed with the latest litigation news. Explore now

Eli Lilly competitive analysis

Latest publications and patents of Eli Lilly New

Explore the latest publications and patents granted to Eli Lilly, showcasing their recent innovations and technological advancements.

Last updated on: Sep 11, 2025
Publication NumberPublication DateTitleLegal Status

Get instant update for new patents of Eli Lilly

Jun 18, 2025Transferrin Receptor Binding Proteins And ConjugatesRequest For Examination Was Made
Jul 3, 2024Novel Imaging Agents For Detecting Neurological DysfunctionPatent Maintained As Amended
Jun 12, 2024Dosage Measurement Module On Injection PenGranted And Under Opposition
May 1, 2024Determination Of A Dose Set And Delivered In A Medication Delivery DeviceGranted And Under Opposition
Feb 7, 2024Methods And Apparatus For Aspects Of A Dose Detection SystemGranted And Under Opposition
Nov 15, 2023Accelerated Testing Method Of Silicone Drainage In SyringesGranted And Under Opposition
Oct 18, 2023Chronic Nightly Dosing Of Lasmiditan For Migraine PreventionGranted And Under Opposition
Aug 23, 2023Dulaglutide For The Treatment Of Chronic Kidney DiseaseGranted And Under Opposition
Aug 2, 2023Gip/Glp1 Agonist CompositionsGranted And Under Opposition
Nov 9, 2022Nasal Powder Formulation For Treatment Of HypoglycemiaPatent Maintained As Amended

Explore patent oppositions filed by Eli Lilly against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Sep 18, 2025
Patent NumberTitleApplicantOpposition Date

Get instant updates on new opposition filings by the company

Il-17 A/F Heterologous Polypeptides And Therapeutics Uses ThereofGENENTECHAug 30, 2021
Il-17 A/F Heterologous Polypeptides And Therapeutics Uses ThereofGENENTECHMar 16, 2020
Antagonist Antibodies Directed Against Calcitonin Gene-Related Peptide And Methods Using SameLABRYS BIOLOGICSDec 7, 2018
Use Of Il-33 Antagonists To Treat Fibrotic DiseaseMERCK SHARP & DOHMEAug 8, 2018
Method For Production Of F-18 Labeled Amyloid Beta LigandsPIRAMAL IMAGINGApr 12, 2018
Use Of A Pcv2 Immunogenic Composition For Lessening Clinical Symptoms In PigsBOEHRINGER INGELHEIM ANIMAL HEALTH USADec 14, 2017

Explore Eli Lilly's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Sep 18, 2025
Patent NumberGrant DateTitleTotal Oppositions
Jul 3, 2024Novel Imaging Agents For Detecting Neurological Dysfunction1
Jun 12, 2024Dosage Measurement Module On Injection Pen1
May 1, 2024Determination Of A Dose Set And Delivered In A Medication Delivery Device1
Feb 7, 2024Methods And Apparatus For Aspects Of A Dose Detection System1
Nov 15, 2023Accelerated Testing Method Of Silicone Drainage In Syringes1
Oct 18, 2023Chronic Nightly Dosing Of Lasmiditan For Migraine Prevention1
Aug 23, 2023Dulaglutide For The Treatment Of Chronic Kidney Disease1
Aug 2, 2023Gip/Glp1 Agonist Compositions7
Nov 9, 2022Nasal Powder Formulation For Treatment Of Hypoglycemia1
Aug 10, 2022Needle Shield Puller Cap Assembly1

Latest PTAB cases involving Eli Lilly New

Discover the latest PTAB cases involving Eli Lilly, highlighting their recent legal challenges and patent disputes.

Last updated on: Sep 17, 2025
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Eli Lilly

IPR2025-01346Aug 4, 2025BPI LABSELI LILLYPending
IPR2025-01024May 22, 2025EMPOWER CLINIC SERVICESELI LILLYPending
IPR2022-00796Apr 11, 2022ELI LILLYTEVA PHARMACEUTICALSFinal Written Decision
IPR2022-00739Mar 23, 2022ELI LILLYTEVA PHARMACEUTICALSFinal Written Decision
IPR2022-00738Mar 23, 2022ELI LILLYTEVA PHARMACEUTICALSFinal Written Decision
PGR2019-00043Apr 2, 2019ELI LILLYGENENTECHTerminated
IPR2018-01712Oct 1, 2018ELI LILLYTEVA PHARMACEUTICALSFinal Written Decision
IPR2018-01711Oct 1, 2018ELI LILLYTEVA PHARMACEUTICALSFinal Written Decision
IPR2018-01710Sep 28, 2018ELI LILLYTEVA PHARMACEUTICALSFinal Written Decision
IPR2018-01427Aug 8, 2018ELI LILLYTEVA PHARMACEUTICALSFinal Written Decision

Top competitors of Eli Lilly

Top competitors of Eli Lilly based on patent oppositions.